[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

July 2018 | 455 pages | ID: R5B08F77DCDEN
La Merie Publishing

US$ 1,690.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:

Negative Immune Checkpoints:
  • PD-1 (programmed cell death 1)
  • PD-L1 (programmed cell death ligand 1 (PD-L1)
  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
  • LAG-3 (Lymphocyte Activation Gene 3; CD223)
  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
  • B7-H3 (CD276)
  • Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4)
Stimulatory Immune Checkpoints:
  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)
Immunosuppressive tumor microenvironment:
  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-?/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4) & othe novel chemokines/receptors
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 – SIRP? (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)
More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
REPORT 1: PD-1 AND PD-L1 IMMUNE CHECKPOINT INHIBITORS 2018

1a) PD-1 Receptor Antagonists:
  Approved and Marketed PD-1 Antagonists
  Specific PD-1 Antagonists in Clinical Development for Regulated Markets
  Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
  Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
  Specific PD-1 Antagonists in Non- or Pre-Clinical Development
  Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development
1b) PD-L1 Inhibitors:
  Approved and Marketed PD-L1 Inhibitors
  Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
  Specific PD-L1 Inhibitors in Non- and Preclinical Development
  Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2) CORPORATE PD-1 AND PD-L1 CHECKPOINT INHIBITOR R&D PIPELINES

REPORT 2: CTLA-4, LAG-3, TIM-3, TIGIT & OTHER IMMUNE CHECKPOINT INHIBITORS 2018

1a) CTLA-4 Receptor Antagonists:
  Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
  Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
  Bispecific CTLA-4 Antagonist in Clinical Development
  Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
  Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D
1b) LAG-3 Antagonists:
  Relatlimab Pipeline
  Selective LAG-3 Antagonists in Clinical Development
  Bispecific LAG-3 Antagonists in Clinical Development
  LAG-3 Antagonists in Non-Clinical Development
  LAG-3 Antagonists in Preclinical R&D
1c) TIM-3 Antagonists:
  Selective and Bispecific TIM-3 Antagonists in Clinical Development
  Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
  TIM-3 Antagonists in Preclinical R&D
1d) TIGIT Antagonists:
  TIGIT Antagonists in Clinical Development
  TIGIT Antagonists in Non-Clinical Development
  TIGIT Antagonists in Preclinical R&D
1e) Other Inhibitors of Negative Immune Checkpoints
  B7-H3 Targeted Immune Checkpoint Inhibitors
Inhibitors of Other Immune Checkpoints

2) CORPORATE INHIBITORS OF NEGATIVE IMMUNE CHECKPOINTS R&D PIPELINES

REPORT 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & OTHER IMMUNE CHECKPOINT ACTIVATORS

  CD40 Agonists
  GITR Agonists
  OX40 Agonists
  4-1BB (CD137) Agonists
  CD27 Agonists1f) ICOS Agonists
  Other Immune Checkpoint Activators

2) CORPORATE IMMUNE CHECKPOINT ACTIVATOR R&D PIPELINES

REPORT 4: TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE PATHWAY & STING 2018

1a) IDO & TDO Inhibitors
  First-Generation Selective IDO-1 Inhibitors
  Novel Selective IDO-1 Inhibitors
  Dual IDO/TDO Inhibitors
  Selective TDO Inhibitors
  Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
  Indirect TGF-beta Inhibition
  Selective TGF-beta1 Inhibitors
  Selective TGF-beta2 Inhibitors
  Dual or Triple TGF-beta Inhibitors
Bispecific TGF-beta Inhibition
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
  CXCR4 Antagonists
  CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
  Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  Other Interleukin Inhibitors
  CCR2/CCR5 Antagonists
  CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
  Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
  CD47 Antagonists
  SIRP? Inhibitors
  Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
  Selective Adenosine A2A Receptor Antagonists
  Selective Adenosine A2B Receptor Antagonists
  Dual Adenosine A2 Receptor Antagonists
  CD73 Ectoenzyme Inhibitors
CD39 Ectoenzyme Inhibitors
Other Approaches
1h) STING Agonists

2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES


More Publications